• 患者服务: 与癌共舞小助手
  • 微信号: yagw_help22

QQ登录

只需一步,快速开始

开启左侧

我父亲肺鳞癌的治疗贴(2014年3月1日驾鹤西去)

    [复制链接]
1271711 1620 老马 发表于 2011-10-27 08:05:18 | 置顶 |
老马  博士一年级 发表于 2012-4-27 18:50:42 | 显示全部楼层 来自: 浙江温州
Pooled Analysis of S-1 Trials in Non-Small Cell Lung Cancer According to Histological Type
: ~* A4 _. S2 Q1 P$ ]; Q1 R( [NOBUYUKI YAMAMOTO1, TAKEHARU YAMANAKA2, YUKITO ICHINOSE3, KAORU KUBOTA4, HIROSHI SAKAI5, AKIHIKO GEMMA6, NAGAHIRO SAIJO7, MASAHIRO FUKUOKA8 and HISANOBU NIITANI9 * }" l, o2 t  ?# M" y
+ Author Affiliations
! `; y. F9 P1 a' n. g2 x7 u! X4 f, u6 a& ?, K4 L, v
1Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka 411-8777, Japan * K4 G+ S% o3 h9 V$ ~4 O
2Cancer Biostatistics Laboratory, Institute for Clinical Research, National Kyushu Cancer Center, Fukuoka 811-1395, Japan " h% l1 A9 b4 a& p
3Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka 811-1395, Japan - k1 G" B. s& R: Q" n0 r* {- S
4Division of Thoracic Oncology, National Cancer Center Hospital, Tokyo 104-0045, Japan
: [4 {7 G- d  s7 x5Division of Thoracic Oncology, Saitama Cancer Center, Saitama 362-0806, Japan
1 d: r8 m% P% R7 u( [( }9 i0 |6Division of Pulmonary Medicine, Infectious Diseases, and Oncology Department of Internal Medicine, Nippon Medical School, Tokyo 113-8603, Japan % F( K  v( G7 [1 b. J. M
7Kinki University School of Medicine, Osaka 589-8511, Japan . j$ h2 F7 h6 }: I! T
8Izumi Municipal Hospital, Osaka 594-0071, Japan , E- W2 \  }1 q$ ?/ |  D* l3 Y
9Tokyo Cooperative Oncology Group, Tokyo 105-0013, Japan
) I3 w" @7 R& l0 ^3 d# N1 U  DCorrespondence to: Nobuyuki Yamamoto, Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka 411-8777, Japan. Tel: +81 559895222, Fax: +81 559895783, e-mail: n.yamamoto@scchr.jp % `& p3 ~7 q" D6 F  }
AbstractBackground: The antimetabolic agent S-1 inhibits thymidylate synthase similar to pemetrexed, but through a different mechanism of action. Whether the antitumour activity of S-1 depends on histological type remains unclear. We analysed pooled data from 2 phase II clinical studies of cisplatin and S-1 in patients with previously untreated advanced non-small cell lung cancer. Patients and Methods: We comprised 110 patients with stage IIIB or IV non–small cell lung cancer. Univariate and multivariate analyses were performed to determine the effects of histological type on progression-free survival and response rates. Results: On pooled analysis of the data, according to histological type, median progression-free survival was 3.8 months in patients with squamous cell carcinoma and 4.4 months in those with non-squamous cell carcinoma. Both analyses showed that progression-free survival and response rate did not differ significantly. Conclusion: Unlike molecular targeted agents and pemetrexed, a combination of cisplatin and S-1 may be no difference in response according to histological type. & o& W! D' m# q# g

* u, K$ a- @5 _. m
个人公众号:treeofhope
老马  博士一年级 发表于 2012-4-27 18:52:43 | 显示全部楼层 来自: 浙江温州
S-1 monotherapy for previously treated non-small cell lung cancer: A retrospective analysis by age and histopathological type
( g+ Z. H1 `8 a1 J8 M& n. e3 W: w0 Q/ @+ Y; I
Authors: Yuki Tomita, Tetsuya Oguri, Osamu Takakuwa, Makoto Nakao, Eiji Kunii, Takehiro  Uemura, Hiroaki Ozasa, Mikinori Miyazaki, Ken Maeno, Shigeki Sato ) a9 y% R8 ]" ]5 N- x5 y+ p$ k% A
) w) {1 ~. n2 A( y' F) V
Affiliations: Department of Medical Oncology and Immunology, Nagoya City University Graduate School of Medical Sciences, Mizuho-cho, Mizuho-ku, Nagoya, Aichi 467-8601, Japan  ) @$ c# ]9 c' c/ z* p  B# d

8 L1 U* L5 C" E0 d6 ?+ V* mPublished online on: Thursday, December 1, 2011   L1 s; z! }0 [1 c

5 C% _6 _* l, q. yDoi: 10.3892/ol.2011.507
: k& O7 m2 e( J
, Q0 F. \( _! rPages: 405-410 / U4 p/ z" w  X! r& J/ G
: a2 C, b( q" P
Abstract:# d: \7 g' T, O2 }- j/ f  \4 u
S-1, an oral fluoropyrimidine derivative, has been approved for the treatment of non-small cell lung cancer (NSCLC) in Japan. In the present study, the efficacy and safety of S-1 monotherapy for elderly patients with previously treated NSCLC were retrospectively evaluated, and the efficacy of S-1 monotherapy was compared by histopathological type. This retrospective study included 54 patients with advanced or recurrent NSCLC who had received S-1 monotherapy following the failure of previous chemotherapy regimens at our institutes. Patient outcomes were compared based on their age and histopathological type. S-1 was administered orally, twice daily, while the duration and interval were modified according to the medical condition of each patient. The default delivery schedule, the mean number of S-1 cycles, did not differ significantly between the two age groups (<70 and ≥70 years). The rate of therapy discontinuation, schedule modification or dose reduction due to intolerable toxicities or patient refusal was relatively frequent in the older group (40.7 and 55.6% for ages <70 and ≥70 years, respectively; p=0.414), and the incidence of grade 3 anemia was relatively high in the older group (3.7 and 18.5%, respectively; p=0.192). The response rates (13.0 and 4.8%, respectively; p=0.609) and disease control rates (39.1 and 33.3%, respectively; p=0.761) did not differ significantly between the two age groups. According to histopathological type, the disease control rate was significantly higher in adenocarcinoma (57.9%) compared to non-adenocarcinoma (20.0%, p=0.013). Thus, S-1 monotherapy may be equally effective and tolerated in patients <70 years and those ≥70 years. Additionally, adenocarcinoma may have a higher disease control rate than non-adenocarcinoma." q$ s) M: l6 a$ [& o
3 q6 U. P2 z% M+ w; s) e3 m  b% s
个人公众号:treeofhope
老马  博士一年级 发表于 2012-4-27 18:57:27 | 显示全部楼层 来自: 浙江温州
Thymidylate synthase (TS) gene expression in primary lung cancer patients: a large-scale study in Japanese population# Y% J5 h. ]3 e' J4 C
F. Tanaka1,*, H. Wada2, Y. Fukui3 and M. Fukushima3
% j5 L  T0 q+ G; u+ Author Affiliations
  K) H0 U' l/ M9 T1Second Department of Surgery, University of Environmental and Occupational Health, Kitakakyushu 8 j0 u- Y: Q, h, G9 I+ A7 b" J0 U
2Department of Thoracic Surgery, Kyoto University, Kyoto
, |* Q( _8 ]( q* ?3Tokushima Research Center, Taiho Pharmaceutical Co. Ltd, Tokushima, Japan 5 V6 B2 u( p& B+ `2 D3 k
&#8629;*Correspondence to: Dr F. Tanaka, Second Department of Surgery, University of Environmental and Occupational Health, 1-1 Isegaoka, Yahata-nishi, Kitakakyushu, 807-8555, Japan. Tel: +81-93-891-7442; Fax: +81-93-692-4004; E-mail: ftanaka@med.uoeh-u.ac.jp 3 d6 @7 V! g, j! J( ~  E! x. @
Received September 3, 2010. + u7 a* }+ v' c7 e8 e0 O
Revision received November 11, 2010.
/ \5 o- l0 u" q2 yAccepted November 17, 2010.
% k  G7 K/ \9 |- S/ yAbstract
& `5 E$ `& r* B7 xBackground: Previous small-sized studies showed lower thymidylate synthase (TS) expression in adenocarcinoma of the lung, which may explain higher antitumor activity of TS-inhibiting agents such as pemetrexed. 2 O- g6 r+ ]) b6 |+ }/ B
Patients and methods: To quantitatively measure TS gene expression in a large-scale Japanese population (n = 2621) with primary lung cancer, laser-captured microdissected sections were cut from primary tumors, surrounding normal lung tissues and involved nodes. 1 J3 X& B9 E! q, m
Results: TS gene expression level in primary tumor was significantly higher than that in normal lung tissue (mean TS/β-actin, 3.4 and 1.0, respectively; P < 0.01), and TS gene expression level was further higher in involved node (mean TS/β-actin, 7.7; P < 0.01). Analyses of TS gene expression levels in primary tumor according to histologic cell type revealed that small-cell carcinoma showed highest TS expression (mean TS/β-actin, 13.8) and that squamous cell carcinoma showed higher TS expression as compared with adenocarcinoma (mean TS/β-actin, 4.3 and 2.3, respectively; P < 0.01); TS gene expression was significantly increased along with a decrease in the grade of tumor cell differentiation. There was no significant difference in TS gene expression according to any other patient characteristics including tumor progression.
" u1 p6 y5 ]- M- h/ |; HConclusion: Lower TS expression in adenocarcinoma of the lung was confirmed in a large-scale study.
% s- W6 T$ M0 \) a4 ?! g3 e
个人公众号:treeofhope
走在异乡  高中一年级 发表于 2012-4-28 00:30:22 | 显示全部楼层 来自: 四川成都
一直关注老马的帖子,前方的指明灯。祝福你爸好疗效
累计签到:1 天
连续签到:1 天
[LV.1]初来乍到
baiselianyi  初中二年级 发表于 2012-4-28 10:24:44 | 显示全部楼层 来自: 浙江台州
一直得到老马帮助,祝福老马爸爸
老马  博士一年级 发表于 2012-4-28 18:00:37 | 显示全部楼层 来自: 浙江温州
26日吃了12片地米(0.75mg一片),27日吃了22片地米(0.75mg 一片),28日吃了12片地米(0.75mg一片),都分二次吃。
' V1 U# I$ _  w7 p; x今天为止没有任何反应,每天吃VC,VB2,还有漱口水,就怕口腔溃疡。
个人公众号:treeofhope
bishop_cn  大学一年级 发表于 2012-4-28 23:16:11 | 显示全部楼层 来自: 中国
副作用如何,单药反应很小吧?
' c6 c7 y: g$ v( D* K- d6 {
老马  博士一年级 发表于 2012-4-29 00:20:00 | 显示全部楼层 来自: 浙江温州
LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based Chemotherapy2 w: [* H& H$ H1 y( S( A; b1 y
http://clinicaltrials.gov/ct2/show/NCT01523587
. P3 k1 J4 u* ^8 r9 p' X  l9 I! \7 `; G' Y/ `0 F! d
BIBW 2992 Plus Simvastatin vs. BIBW 2992 in Previously Treated Patients With Advanced Non-adenocarcinomatous NSCLC
" m8 [, K& M9 }- l; lhttp://clinicaltrials.gov/ct2/show/NCT01156545
个人公众号:treeofhope
老马  博士一年级 发表于 2012-4-29 20:53:58 | 显示全部楼层 来自: 浙江温州
本帖最后由 老马 于 2012-4-30 09:33 编辑
: B3 y$ }& d9 P3 I  f/ H% }4 F, |
从4月24日开始到4月28日,打了5天的舒普深(注射用头孢哌酮钠舒巴坦钠),效果非常好。
5 K' J6 _% b; k, A至今为止,未出现化疗副作用。
个人公众号:treeofhope
英雄武松  大学四年级 发表于 2012-4-30 01:37:05 | 显示全部楼层 来自: 哈萨克斯坦
老马 发表于 2012-4-29 20:53
% X/ M8 E; v2 E% m" y) b- X3 S# A从4月24日开始到4月28日,打了5天的打了5天舒普深(注射用头孢哌酮钠舒巴坦钠),效果非常好。
! r: _7 ]; _1 E- a7 x至今为止,未出 ...

4 z8 s. w9 l; G$ T" Z没有副作用是第一追求,效果显著是第二追求。
9 l7 x5 ?' {0 W* g不错。

发表回复

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

  • 回复
  • 转播
  • 评分
  • 分享
帮助中心
网友中心
购买须知
支付方式
服务支持
资源下载
售后服务
定制流程
关于我们
关于我们
友情链接
联系我们
关注我们
官方微博
官方空间
微信公号
快速回复 返回顶部 返回列表